Clinical experience with intravenous valproate as first-line treatment of status epilepticus and seizure clusters in selected populations

Objective: The aim of this study was to evaluate the efficacy and safety of intravenous valproate (i.v. VPA) as first-line treatment of status epilepticus (SE) and seizure clusters in selected patient populations. Methods: We enrolled 23 patients (11 females and 12 males; mean age: 61 years) with SE who received i.v. VPA as first-line therapy (25 mg/kg in 100 mL saline infused over 15 min). ECG tracing was monitored before, during, and after infusion. Liver function and serum ammonia tests were conducted after 24 and 72 h of treatment. We evaluate the response of SE to i.v. therapy and short-term outcome. Results: In 15 out of 23 patients (65%), i.v. VPA was effective. In our population, we retrospectively identified three different subgroups: patients with cardiorespiratory comorbidities discouraging the use of traditional SE first-line drugs, patients with specific epileptic subsyndromes (such as idiopathic generalized epilepsy), and patients affected by psycho-organic syndromes. No significant adverse effects were detected. Discussion: Our study shows the clinical relevance of i.v. VPA as first-line therapy of SE in patients with medical conditions contraindicating the use of traditional first-line antiepileptic drugs for SE, and in those presenting with specific forms of SE.

[1]  N. Khosroshahi,et al.  Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial. , 2012, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[2]  J. Zhao,et al.  Valproate versus diazepam for generalized convulsive status epilepticus: a pilot study , 2011, European journal of neurology.

[3]  B. Burnand,et al.  Second‐line status epilepticus treatment: Comparison of phenytoin, valproate, and levetiracetam , 2011, Epilepsia.

[4]  Simon Shorvon,et al.  The treatment of status epilepticus. , 2011, Current opinion in neurology.

[5]  S. Shorvon,et al.  EFNS guideline on the management of status epilepticus in adults , 2010, European journal of neurology.

[6]  K. Sawanyawisuth,et al.  Predictors and prognosis of status epilepticus treated with intravenous sodium valproate. , 2009, Epileptic disorders : international epilepsy journal with videotape.

[7]  Y. Lampl,et al.  Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin , 2008, Acta neurologica Scandinavica.

[8]  A. Berardelli,et al.  Status epilepticus in epileptic patients Related syndromes, precipitating factors, treatment and outcome in a video-EEG population-based study , 2008, Seizure.

[9]  E. Trinka The use of valproate and new antiepileptic drugs in status epilepticus , 2007, Epilepsia.

[10]  P. Singhi,et al.  Intravenous Sodium Valproate Versus Diazepam Infusion for the Control of Refractory Status Epilepticus in Children: A Randomized Controlled Trial , 2007, Journal of child neurology.

[11]  M. Holtkamp,et al.  Non-convulsive status epilepticus in adults: clinical forms and treatment , 2007, The Lancet Neurology.

[12]  A. Rossetti Sodium valproate vs phenytoin in status epilepticus: A pilot study , 2007, Neurology.

[13]  E. Perucca,et al.  Treatment of Status Epilepticus in Adults: Guidelines of the Italian League Against Epilepsy , 2006, Epilepsia.

[14]  E. Trinka,et al.  Acute encephalopathy after intravenous administration of valproate in non‐convulsive status epilepticus , 2006, European journal of neurology.

[15]  C. N. Peters,et al.  Intravenous valproate as an innovative therapy in seizure emergency situations including status epilepticus—experience in 102 adult patients , 2005, Seizure.

[16]  R F M Chin,et al.  A systematic review of the epidemiology of status epilepticus , 2004, European journal of neurology.

[17]  K. Yu,et al.  Safety and Efficacy of Intravenous Valproate in Pediatric Status Epilepticus and Acute Repetitive Seizures , 2003, Epilepsia.

[18]  P. Garcia,et al.  Incidence and mortality of generalized convulsive status epilepticus in California , 2002, Neurology.

[19]  S. Krähenbühl,et al.  Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. , 2000, Liver.

[20]  R. Trollmann,et al.  Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus , 2000, Neurology.

[21]  J. Wheless,et al.  Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients , 1999, Epilepsy Research.

[22]  D. Naritoku,et al.  Intravenous loading of valproate for epilepsy. , 1999, Clinical neuropharmacology.

[23]  J. Wheless,et al.  Safety of high intravenous valproate loading doses in epilepsy patients , 1998 .

[24]  Y. Inoue,et al.  Long‐Term Course of West Syndrome Associated with Tuberous Sclerosis , 1998, Epilepsia.

[25]  M. Parsonage Dictionary of epilepsy, part 1 (definitions) , 1974 .

[26]  J. Stockman Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study , 2008 .

[27]  R. Delorenzo,et al.  Treatment of convulsive status epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus. , 1993, JAMA.

[28]  H. Gastaut,et al.  Dictionary of epilepsy , 1973 .